Moderna authorised to upscale development of mRNA vaccines in UK
Ella Day | April 15, 2025 | News story | Manufacturing and Production | Moderna, UK, UK government, Virology, mrna, vaccination
Global researcher of mRNA medicine, Moderna, has been granted authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) to manufacture commercial mRNA vaccines at its facility in Harwell, Oxfordshire, UK. This is a milestone in Moderna’s mission to develop a reliable supply of mRNA vaccines for pandemic-preparedness.
The MHRA granted Manufacturer’s/Importer’s Authorisation (MIA) to the Modern Innovation and Technology Centre (MITC). Operations have been permitted following a successful inspection that confirmed the facility’s compliance with the principles and guidelines of Good Manufacturing Practice (GMP).
The establishment forms part of a ten-year strategic partnership between Moderna and the UK government, overseen by the UK Health Security Agency (UKHSA) aiming to bolster pandemic preparedness. Together, they seek to produce at least 250 million doses during a pandemic for the NHS and UK public.
“This significant achievement marks a major step forward in our mission to establish end-to-end mRNA manufacturing capabilities in the UK,” said Darius Hughes, UK general manager of Moderna. He added that it “brings the company closer to ensuring a reliable, onshore supply of mRNA vaccines within the UK”.
Additionally, the initiative seeks to strengthen the UK’s influence in clinical research and scientific development. Hughes expressed that “[Moderna is] proud to be contributing to the UK’s growth mission”.
The Oxfordshire site forms one of many, with additional sites in Canada and Australia, strategically located to ensure a quick and efficient rollout of vaccinations where needed.
Ella Day
15/4/25
Related Content
Rollout of world-first gonorrhoea vaccine programme begins under NHS
From 4 August, sexual health clinics in England have been able to offer a free …
Addenbrooke’s hospital offers first self-service digital eye test
Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing …
Moderna doses first US patient in phase 1 trial of mRNA-4106 for solid tumours
The START Center for Cancer Research has dosed the first US participant in Moderna’s phase …
